Cellectar positive Phase 2b data supporting FDA accelerated approval in Waldenström macroglobulinemia
Cellectar Biosciences posts positive Phase 2b CLOVER WaM data supporting FDA accelerated approval path for iopofosine I 131 in Waldenström macroglobulinemia
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.